title: Folliculotropic mycosis fungoides responding to bexarotene gel.
abstract: Folliculotropic mycosis fungoides (FMF) is an uncommon and potentially aggressive form of cutaneous T cell lymphoma (CTCL). Phototherapy, radiotherapy, and systemic chemotherapy are the most commonly employed treatment options, but may have limited success and common adverse reactions. Bexarotene gel is a topical retinoid X receptor (RXR) agonist with activity on the follicular unit that has not been previously reported in the management of FME The case of a 73-year-old male with FMF that responded to bexarotene gel is presented.
authors.affiliation: Town Square Dermatology, Coralville, IA 52241, USA. hobartwalling@yahoo.com
authors.forename: Hobart W
authors.initials: HW
authors.lastname: Walling
authors.forename: Brian L
authors.initials: BL
authors.lastname: Swick
authors.forename: Pedram
authors.initials: P
authors.lastname: Gerami
authors.forename: Richard K
authors.initials: RK
authors.lastname: Scupham
mesh_terms: D000368:Aged; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D000077610:Bexarotene; D005782:Gels; D006801:Humans; D008297:Male; D009182:Mycosis Fungoides / Q000188:drug therapy* / Q000473:pathology; D013764:Tetrahydronaphthalenes / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D016588:Anticarcinogenic Agents; D005782:Gels; D013764:Tetrahydronaphthalenes; D000077610:Bexarotene